Clinical Scorecard: Assessing the Histological Representativeness of Tissue Samples in Glioblastoma

At a Glance

Key Highlights

• GBMs exhibit extensive histopathological heterogeneity, increasing risk of non-representative biopsy samples and potential undergrading.
• Diagnosis integrates histological features and molecular markers, including IDH mutation status per WHO 2016 classification.
• Tissue sample size correlates with diagnostic accuracy; smaller viable tissue areas may reduce detection of key histological features.

Guideline-Based Recommendations

Diagnosis

• Use combined histological and molecular analyses (including IDH mutation status) for GBM diagnosis per WHO CNS tumor classification.
• Ensure adequate viable tissue sampling to capture mandatory grade IV features (microvascular proliferation or necrosis).
• Consider advanced molecular profiling (e.g., methylation profiling) where available to improve diagnostic accuracy.

Management

• Standard treatment involves maximal tumor resection followed by concomitant radiochemotherapy.
• Surgical sampling should aim to maximize viable tumor tissue for accurate histopathological assessment.

Monitoring & Follow-up

• Preoperative MRI with T1-weighted contrast-enhanced imaging to assess tumor volume and guide surgical planning.
• Histopathological evaluation of multiple tissue blocks and slides to mitigate sampling bias.

Risks

• Sampling errors due to tumor heterogeneity may lead to histological undergrading and misclassification.
• Limited availability of comprehensive molecular analyses may restrict diagnostic precision in some institutions.

Patient & Prescribing Data

Adults with newly diagnosed glioblastoma undergoing surgical intervention and histopathological diagnosis

Maximal tumor resection with adjuvant radio-chemotherapy remains standard; accurate histological and molecular diagnosis guides treatment planning.

Clinical Best Practices

• Obtain multiple and sufficiently large viable tissue samples during surgery to improve histological representativeness.
• Integrate histological features with molecular markers, especially IDH mutation status, for accurate GBM classification.
• Utilize preoperative MRI volumetrics to inform surgical and sampling strategies.
• Recognize limitations of small biopsy samples and consider additional molecular testing when feasible.
• Document and categorize tissue amount on HE slides to assess sample adequacy.

References

• WHO Classification of Tumors of the Central Nervous System, 2016
• Stensjøen et al., Preoperative growth dynamics of GBMs
• Gutt-Will et al., Tissue volume estimation in GBM